keyboard_arrow_up

Global Hemophilia Industry 2015: Market Size, Share, Growth Drivers, Trends and Forecasts

MarketReportsOnline.com adds "Global Hemophilia Market Report: 2015 Edition" report to its research store.

Hemophilia is an inherited or acquired bleeding disorder that prevents blood from clotting. People with hemophilia lack, either partially or completely, an essential clotting factor needed to form stable blood clots. People with hemophilia do not bleed any faster than normal, but they can bleed for a longer time. Hemophilia is quite rare and about 1 in 10,000 people are born with it, around 0.42 million people live with hemophilia. Hemophilia patients need to replace the missing factor through infusions. The main treatment is called replacement therapy, in which concentrates of clotting factor VIII (for hemophilia A) or clotting factor IX (for hemophilia B) are injected into a vein. More people suffer with hemophilia A in comparison to hemophilia B and Inhibitors. The US accounts for the major population suffering with hemophilia globally.

Complete report available at http://www.marketreportsonline.com/409838.html.

The key trends observed in the market include introduction of new products increased competition in rFVIII market and adoption of prophylactic treatment. On the development front, there has been an increase in the launch of new products like next-Generation long-acting Factor VIII and ready-to-use product by Novo Nordisk. But there are certain challenges too which include high risk and cost associated with new drugs, rising cost of hemophilia treatment and low switching rate among patients. The future drivers of the industry are increased rate of diagnosis and treatment, rising male population and global healthcare expense among others.

The report provides a comprehensive study of hemophilia market globally and also provides detailed information for key regional markets. The competition in the global hemophilia market is intense among large players like Baxter International Inc., Novo Nordisk and Pfizer. All these companies have been profiled in the present report highlighting their key financials and business strategies for growth.

Purchase a copy of this research report at USD 800 (Single User License) http://www.marketreportsonline.com/contacts/purchase.php?name=409838.

By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.

Table of Contents:

1. Overview

2. Market Analysis

2.2 Hemophilia Market by Segments

2.3 Regional Analysis


3. Market Dynamics

3.1 Growth Drivers

3.2 Key Trends

3.3 Challenges

3.4 Significant Developments

 

4. Competitive Landscape

4.1 Global

4.2 The US

 

5. Company Profiles

5.1 Baxter International Inc.

5.2 Novo Nordisk

5.3 Pfizer, Inc.

 

6. Market Outlook

6.1 Market Forecast

6.2 Forecast Methodology

 

List of Tables

List of Charts

Other Related Reports on Pharmaceuticals Market:

US Thyroid Cancer Market: Trends and Opportunities (2015 - 2019)

Global Biosimilar Market Trends & Opportunities: 2015 Edition

US Pharmacy Benefit Management (PBM) Industry Report

Global Knee & Hip Market Report: 2014 Edition

About Us: MarketReportsOnline comprises of an online library of 2,50,000 reports and in-depth market research studies of over 5000+ micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

Contact Us:
Ritesh Tiwari
Corporate Office
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252.
Tel: + 1 888 391 5441
E-mail: sales@marketreportsonline.com